The ACR has released a summary of a new 2024 guideline for the screening, treatment, and management of Lupus Nephritis.

There are multiple chapters near you. Select your preferred chapter.

The glucose-lowering and weight-reducing drug class appears to benefit the heart and kidneys in people with lupus and lupus nephritis, independently of glucose-lowering and weight loss.

A noninvasive urinary biomarker panel predicts lupus nephritis activity and response better than proteinuria, and, if further validated, may aid diagnosis and gauge treatment response, investigators ...

Two studies presented at the 2024 American College of Rheumatology (ACR) Annual Meeting revealed that GLP-1 receptor agonists ...

WASHINGTON -- Lupus nephritis (LN) diagnosis could improve greatly if early results with a multimarker urine test are ...

This report report provides comprehensive insights about 30+ companies and 35+ pipeline drugs in Lupus Nephritis pipeline landscape. It covers the pipeline drug profiles, including clinical and ...

Studies investigating what is damaging the kidney in lupus nephritis point to tubulointerstitial inflammation.

Aurinia Pharmaceuticals (AUPH) has released an update.Don't Miss our Black Friday Offers:Discover the latest stocks recommended by top Wall ...

BioNxt reports expansion of its next-generation product pipeline with innovative solutions for autoimmune diseases and longevity: Vancouver, BC Wednesday, November 27, 2024, 17:00 ...

Detailed price information for Aurinia Pharm Ord (AUPH-Q) from The Globe and Mail including charting and trades.